Home » Stocks » VCNX

Vaccinex, Inc. (VCNX)

Stock Price: $2.23 USD 0.00 (0.00%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $2.20 -0.03 (-1.35%) May 7, 7:53 PM
Market Cap 63.42M
Revenue (ttm) 625,000
Net Income (ttm) -28.85M
Shares Out 28.44M
EPS (ttm) -1.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $2.23
Previous Close $2.23
Change ($) 0.00
Change (%) 0.00%
Day's Open 2.20
Day's Range 2.19 - 2.33
Day's Volume 180,477
52-Week Range 1.63 - 9.56

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CLASSICAL-Lung study evaluated pepinemab in combination with the checkpoint inhibitor BAVENCIO® for the treatment of non-small cell lung cancer CLASSICAL-Lung study evaluated pepinemab in combination wi...

2 weeks ago - GlobeNewsWire

Reported top-line results from Phase 2 SIGNAL study that indicates potential cognitive benefit of pepinemab in neurodegenerative disease. New Alzheimer's study expected to begin enrollment in Q2

1 month ago - GlobeNewsWire

Novavax (NASDAQ: NVAX) shares are trading higher Friday after the company announced a Memorandum of Understanding with Gavi to provide 1.1 billion cumulative doses of NVX-CoV2373. Novavax is a biotechno...

Other stocks mentioned: EOLS, NVAX
2 months ago - Benzinga

Vaccinex (VCNX) stock is rocketing higher on Friday after following an announcement about multi-project deals with two comapnies. The post VCNX Stock: 11 Things to Know About Vaccinex and the Deals That...

2 months ago - InvestorPlace

Shares of micro-cap biopharma Vaccinex Inc (NASDAQ: VCNX) were trading higher Friday on above-average volume. Rochester, New York-based Vaccinex, which focuses on therapies for cancer and neurodegenerat...

2 months ago - Benzinga

Vaccinex Inc (NASDAQ: VCNX) jumps premarket in reaction to multi-project deals signed with two undisclosed prominent pharmaceutical companies, utilizing Vaccinex's ActivMAb, antibody discovery, and nove...

2 months ago - Benzinga

Partnerships will use Vaccinex's ActivMAb® platform for viral display of complex antigens to enable antibody discovery Partnerships will use Vaccinex's ActivMAb® platform for viral display of complex an...

2 months ago - GlobeNewsWire

Want to try some out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Other stocks mentioned: BJ, BLCM, LMNL, QFIN, VIVO
4 months ago - Zacks Investment Research

ROCHESTER, N.Y., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative dis...

4 months ago - GlobeNewsWire

Addition al data from SIGNAL Huntington's disease (HD) trial support continued development in H D and in Alzheimer's disease (AD)

5 months ago - GlobeNewsWire

SIGNAL Phase 2 trial data continue to support cognitive benefit and reduced brain atrophy with pepinemab treatment in Huntington's disease

6 months ago - GlobeNewsWire

SIGNAL Phase 2 trial data continue to support cognitive benefit and reduced brain atrophy with pepinemab treatment in Huntington's disease

6 months ago - GlobeNewsWire

Live moderated video webcast discussion between members of management and Key Opinion Leader, Eric Siemers, MD on Tuesday, October 27th at 10:00 a.m. EDT Live moderated video webcast discussion between ...

6 months ago - GlobeNewsWire

Investors need to pay close attention to Vaccinex (VCNX) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

Shares of micro-cap immunotherapy company Vaccinex Inc (NASDAQ: VCNX) were plunging Tuesday in reaction to an adverse readout.

7 months ago - Benzinga

Shares of Vaccinex Inc. tumbled 61.6% in premarket trading on Tuesday after the preclinical biotechnology company said an experimental Huntington's disease treatment, pepinemab, did not meet the primar...

7 months ago - Market Watch

K ey cognitive endpoint s trending towards but did not reach statistical significance in early manifest population . O verall study does not meet pre-specified co- primary endpoints

7 months ago - GlobeNewsWire

ROCHESTER, N.Y., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a novel approach to treating cancer and neurodegenerative disease t...

7 months ago - GlobeNewsWire

ROCHESTER, N.Y., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Huntington’s disease (HD...

8 months ago - GlobeNewsWire

Vaccinex, Inc. (VCNX) delivered earnings and revenue surprises of 23.53% and -100.00%, respectively, for the quarter ended June 2020.

8 months ago - Zacks Investment Research

On track to report potentially pivotal Phase 2 Huntington’s disease topline data by early October

8 months ago - GlobeNewsWire

Vaccinex, Inc. (VCNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

9 months ago - Zacks Investment Research

Inside the top-ranked stocks that have been exhibiting rising price-to-earnings ratios.

Other stocks mentioned: AVGR, BLRX, PTI, VIVE
9 months ago - Zacks Investment Research

Vaccinex (VCNX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

Topline data anticipated in October 2020 as previously guided Topline data anticipated in October 2020 as previously guided

10 months ago - GlobeNewsWire

Live video moderated discussion with President and CEO, Maurice Zauderer, Ph.D., on Tuesday, June 16, at 10:00 AM ET, immediately followed by an interactive Q&A session

11 months ago - GlobeNewsWire

Vaccinex Inc (VCNX) delivered earnings and revenue surprises of 8.16% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Approaching key topline data in non-small cell lung cancer and Huntington’s disease

11 months ago - GlobeNewsWire

Data continue to demonstrate durable response in patients as trial nears completion Data continue to demonstrate durable response in patients as trial nears completion

11 months ago - GlobeNewsWire

Vaccinex Inc (VCNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

11 months ago - Zacks Investment Research

Updated data continue to demonstrate a durable clinical benefit in both immunotherapy-naïve patients as well as those previously treated with an immunotherapy regimen Updated data continue to demonstrat...

1 year ago - GlobeNewsWire

Presentation highlighted the potential of the company’s lead candidate, the anti-SEMA4D antibody pepinemab, to regulate glial cell activation and neurodegeneration in Alzheimer’s and Huntington’s diseas...

1 year ago - GlobeNewsWire

Key trials in Huntington’s disease and non-small cell lung cancer are near completion; company working with trial sites to assess delays and determine the most efficient path to topline data Key trials ...

1 year ago - GlobeNewsWire

Pepinemab (VX15), an experimental Vaccinex drug previously shown to prevent reduced brain glucose transport in Huntington’s disease, will be tested for similar effects in Alzheimer’s disease Pepinemab (...

1 year ago - GlobeNewsWire

ROCHESTER, N.Y., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s...

1 year ago - GlobeNewsWire

ROCHESTER, N.Y., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s...

1 year ago - GlobeNewsWire

Vaccinex (VCNX) completes enrollment in a phase Ib/II study of its pipeline candidate pepinemab in combination with Bavencio for treating advanced non-small cell lung cancer.

1 year ago - Zacks Investment Research

President and CEO of Vaccinex Inc (30-Year Financial, Insider Trades) Maurice Zauderer (insider trades) bought 183,824 shares of VCNX on 07/30/2019 at an average price of $4.08 a share.

1 year ago - GuruFocus

About VCNX

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that is in Phase 1 and 2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alz... [Read more...]

Industry
Biotechnology
Founded
2001
Stock Exchange
NASDAQ
Ticker Symbol
VCNX
Full Company Profile

Financial Performance

In 2020, Vaccinex's revenue was $625,000, an increase of 19.50% compared to the previous year's $523,000. Losses were -$28.85 million, -9.45% less than in 2019.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for Vaccinex stock is "Buy." The 12-month stock price forecast is 7.00, which is an increase of 213.90% from the latest price.

Price Target
$7.00
(213.90% upside)
Analyst Consensus: Buy